On a path to transform the battery metals industry, Technology Minerals PLC is set to submit an application for the admission of 10,362,520 additional ordinary shares. This move is an extenuation of the company’s previous announcements made on the 20th of December 2024, and January 7, 2025. These shares are to be issued to Atlas Capital Markets LLC, thus bolstering the company’s monetary position.
The total funds projected to be drawn from the £5.5 million facility with ACM post-conversion will remain standing at £2.5million, with £820,000 set to be converted into ordinary shares. This reflects an outstanding principal balance of £1.68 million.
In a critical development, global biopharmaceutical company CureVac N.V.’s European patent, dubbed EP 3 708 668 B1, has been confirmed as valid by the European Patent Office (EPO). This decision is a notable landmark in the company’s ongoing intellectual property dispute with BioNTech SE in Germany, which involves a total of six intellectual property rights. BioNTech SE had challenged the patent’s validity back in April 2023, but the EPO maintained the patent in an amended form following the recent hearing.
This favourable ruling sets the tone for further proceedings, as the Regional Court Düsseldorf is expected to make a decision on whether the patent has been infringed in its altered form. A hearing on this matter is earmarked for July 1,2025. A verdict in favour of CureVac would trigger an additional process to assess damages.